Konstantinopoulos PA - Search Results

1

Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer.

Konstantinopoulos PA, Wilson AJ, Saskowski J, Wass E, Khabele D. Konstantinopoulos PA, et al. Gynecol Oncol. 2014 Jun;133(3):599-606. doi: 10.1016/j.ygyno.2014.03.007. Epub 2014 Mar 11. Gynecol Oncol. 2014. PMID: 24631446 Free PMC article.

2

Gene-expression profiling in epithelial ovarian cancer.

Konstantinopoulos PA, Spentzos D, Cannistra SA. Konstantinopoulos PA, et al. Nat Clin Pract Oncol. 2008 Oct;5(10):577-87. doi: 10.1038/ncponc1178. Epub 2008 Jul 22. Nat Clin Pract Oncol. 2008. PMID: 18648354 Review.

3

Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.

Konstantinopoulos PA, Spentzos D, Karlan BY, Taniguchi T, Fountzilas E, Francoeur N, Levine DA, Cannistra SA. Konstantinopoulos PA, et al. J Clin Oncol. 2010 Aug 1;28(22):3555-61. doi: 10.1200/JCO.2009.27.5719. Epub 2010 Jun 14. J Clin Oncol. 2010. PMID: 20547991 Free PMC article.

4

Current status and evolution of preclinical drug development models of epithelial ovarian cancer.

Konstantinopoulos PA, Matulonis UA. Konstantinopoulos PA, et al. Front Oncol. 2013 Dec 11;3:296. doi: 10.3389/fonc.2013.00296. Front Oncol. 2013. PMID: 24377084 Free PMC article. Review.

5

PARP inhibitors in ovarian cancer: current status and future promise.

Liu JF, Konstantinopoulos PA, Matulonis UA. Liu JF, et al. Among authors: konstantinopoulos pa. Gynecol Oncol. 2014 May;133(2):362-9. doi: 10.1016/j.ygyno.2014.02.039. Epub 2014 Mar 4. Gynecol Oncol. 2014. PMID: 24607283 Review.

6

Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells.

Choi YE, Battelli C, Watson J, Liu J, Curtis J, Morse AN, Matulonis UA, Chowdhury D, Konstantinopoulos PA. Choi YE, et al. Among authors: konstantinopoulos pa. Oncotarget. 2014 May 15;5(9):2678-87. doi: 10.18632/oncotarget.1929. Oncotarget. 2014. PMID: 24798692 Free PMC article.

7

An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancer.

Shah MM, Dobbin ZC, Nowsheen S, Wielgos M, Katre AA, Alvarez RD, Konstantinopoulos PA, Yang ES, Landen CN. Shah MM, et al. Among authors: konstantinopoulos pa. Gynecol Oncol. 2014 Aug;134(2):331-7. doi: 10.1016/j.ygyno.2014.05.009. Epub 2014 May 15. Gynecol Oncol. 2014. PMID: 24844596 Free PMC article.

8

A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance.

Ceccaldi R, O'Connor KW, Mouw KW, Li AY, Matulonis UA, D'Andrea AD, Konstantinopoulos PA. Ceccaldi R, et al. Among authors: konstantinopoulos pa. Cancer Res. 2015 Feb 15;75(4):628-34. doi: 10.1158/0008-5472.CAN-14-2593. Epub 2015 Jan 29. Cancer Res. 2015. PMID: 25634215 Free PMC article.

9

Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair.

Ceccaldi R, Liu JC, Amunugama R, Hajdu I, Primack B, Petalcorin MI, O'Connor KW, Konstantinopoulos PA, Elledge SJ, Boulton SJ, Yusufzai T, D'Andrea AD. Ceccaldi R, et al. Among authors: konstantinopoulos pa. Nature. 2015 Feb 12;518(7538):258-62. doi: 10.1038/nature14184. Epub 2015 Feb 2. Nature. 2015. PMID: 25642963 Free PMC article.

10

Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer.

Konstantinopoulos PA, Ceccaldi R, Shapiro GI, D'Andrea AD. Konstantinopoulos PA, et al. Cancer Discov. 2015 Nov;5(11):1137-54. doi: 10.1158/2159-8290.CD-15-0714. Epub 2015 Oct 13. Cancer Discov. 2015. PMID: 26463832 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

192 results

Search Page